Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024.
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Arcutis Presents Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast
Arcutis Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis
Arcutis Announces Closing of Public Offering of Common Stock
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.